BioIDEA and EVQLV hosted a panel discussion and Q&A on the role of emerging technologies in the fight against COVID-19.
The event was fantastic. Our panelists included Elena Diez Cecilia, Director of Business Development and R&D Strategy at A2A Pharmaceuticals, Ed Painter, Chairman and CIO of A2A Pharmaceuticals; Peter Leonardi, CEO and Founder of OmniCyte; and our very own Andrew Satz, CEO and Co-Founder of EVQLV.
Watch the event below.
0 Comments